Shoshanna Fischhoff

Dr. Feldman spoke about the importance of researching clusters in ALS.

A new grant will fund study of an immune cell that may represent a potential target for treating the disease.

Research found that despite changes in guidelines for peripheral neuropathy testing, actual practices had not changed.

Celebrating the brain science happening at the NeuroNetwork for Emerging Therapies.

The American Neurological Association highlighted Eva L. Feldman, M.D., Ph.D.’s, past tenure as president.

Researcher observed that changes in metabolism was linked to ALS progression.

The move for Frances and Kenneth Eisenberg Emerging Scholar Kevin Chen, M.D., solidifies and furthers his research endeavors.

The American Brain Foundation presented Melissa Elafros, M.D., Ph.D., with the Mridha Spirit of Neurology Award for her work improving care for those most in need.

Five new board members share a personal experience with ALS and a commitment to advancing care and research for the devastating disease.

Dr. Feldman was interviewed by Health about research that says that "Weekend Warriors Can Still Reap Brain Health Benefits from Exercise."

The Mitchell B. Max Award for Neuropathic Pain was awarded to Brian Callaghan, M.D., M.S., by the American Academy of Neurology.

In one of the world’s leading journals, The Lancet Neurology, Drs. Eva Feldman and Stephen Goutman join key international neurologists to publish recommendations based on new models of research, collaboration, and funding that could transform ALS into a livable condition for patients globally.

Eva L. Feldman, M.D., Ph.D., published a “Viewpoint” in JAMA Neurology that advocates for a new model to improve ALS research and care.

In a letter to the editor in Journal of the Peripheral Nervous System, a group led by Drs. Eva Feldman and Stephanie Eid makes a case for increased efforts in peripheral neuropathy research. Here are some of the issues they raise:

NIH support will allow Brian Callaghan, M.D., to study the medical and cost effectiveness of new Alzheimer’s medications in underrepresented communities.